About AEI My AEI Support AEI Contact AEI
Home Events Books Short Publications Research Areas Scholars & Fellows


Search


FindAdvanced Search

Browse all short publications by:
- Date
- Subject
- Author
- Type
- Title

SHORT PUBLICATIONS
AEI Newsletter
AEI.org Exclusives
The American
Press Releases
Outlook Series
On the Issues
Papers and Studies
AEI Working Paper Series
Government Testimony
Speeches
Book Reviews
AEI Policy Series
The War on Terror

E-NEWSLETTERS
Enter e-mail:
 

Home >  Short Publications >  Private Sector and Public Sector Malaria Treatment in Africa
Private Sector and Public Sector Malaria Treatment in Africa
Print Mail
By Roger Bate
Posted: Thursday, July 3, 2008
PAPERS AND STUDIES
Africa Fighting Malaria  
Publication Date: July 1, 2008

Download file Click here to view this paper as an Adobe Acrobat PDF.

Improving access to good quality drugs is a crucial element of malaria control. Ensuring high standards for medicines as well as medical treatment will be essential in preserving the efficacy of the current first line treatment, Artemisinin-based combination therapy (ACT). Although public funding for malaria control has increased markedly in recent years to approximately $1.3 billion in 2007[1], the majority of Africans in high malaria burden countries access treatment through the private sector. With some exceptions, publicly financed treatment programs have had limited penetration into rural areas of sub-Saharan Africa, where the malaria burden is greatest. General shops, pharmacies and hawkers are ubiquitous resources. Because these outlets are poorly regulated, the quality, price and administration of anti-malarials vary significantly. Drug resistance to artemisinin has already been established in South East Asia and could spread to Africa. The use and misuse of substandard drugs could accelerate parasite resistance to artemisinin, which would be devastating for malaria control.

Much media and advocacy attention has been directed toward new discoveries of antimalarial treatment, and relatively little toward the mechanisms for delivering treatments to those in need. A major exception is the proposed Affordable Medicines Facility--malaria, which has the potential to increase access to medicines and should be commended for targeting the private sector. However, for mechanisms such as this to effectively deliver medicines to those most in need, more targeted research is needed on the market for antimalarials and the business models of general stores and traders in remote rural areas. . . .

Download file Click here to view this paper as an Adobe Acrobat PDF.

Roger Bate is a resident fellow at AEI.

Notes

1. 14th RBM Partnership Board Meeting Presentations. Executive Director’s Report. Roll Back Malaria Partnership. Available: http://www.rbm.who.int/partnership/board/meetings/ppt/14pbm/14pbm_ed.pdf

Related Links
Related paper on malaria in Africa by Bate
Related article on antimalarial drug quality by Bate
Related book by Bate: Making a Killing


Also by Roger Bate
Recent Articles
Got Contaminated Milk?
Good Move on Bad Drugs
Mugabe's Death Grip
Latest Book
Making a Killing
The Deadly Implications of the Counterfeit Drug Trade
On the Issues

On the Issues  
In the most recent installment of On the IssuesMichael Auslin says that Japan's new prime minister, Taro Aso, must quickly devise a realistic plan to reform Japan's economy and justify its global role if he and his Liberal Democratic Party are to survive.


Making a Killing
Making a Killing

In Making a Killing: The Deadly Implications of the Counterfeit Drug Trade, AEI resident fellow Roger Bate analyzes the burgeoning international trade in counterfeit drugs and recommends steps that governments and law enforcement agencies could take to stop it.